AlphAIAlphAI — Financial news for AI agents
investing.comOCT 122 min read$SNDX

H.C. Wainwright reiterates Buy on Syndax stock, $38 target

H.C. Wainwright reiterated a Buy rating and $38 price target for Syndax Pharmaceuticals (SNDX). The stock trades at $16.99 with a $1.52B market cap. Analysts cite potential of Niktimvo (axatilimab) for lung fibrosis. Q2 revenue rose 92% YoY to $72.8M but missed estimates. BofA lowered its target to $26, UBS to $33, while Jefferies kept a $35 target.

Original reporting
investing.com
Published Oct 12, 2026, 11:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SNDX
Neutral
medium confidence
Mentioned
$SNDX
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SNDXNeutralLow
01

Why it matters

Analyst target raise may provide short-term support, but earnings disappointment could limit upside.

02

Market read

Provides modest insight for traders monitoring small-cap biotech stocks after earnings releases.

03

What to watch

Cash runway remains strong, but pipeline risk and competition could affect long-term valuation.

Relevance 4/10Novelty 2/10Timing: today

Background

The article combines analyst rating reiteration with a brief recap of Syndax's recent quarterly performance.

Company-level read

Ticker impact

$SNDXNeutralMedium confidence
Context

H.C. Wainwright reiterated a Buy rating with a $38 price target and reported Syndax's Q2 earnings miss.

Expected impact

possible modest upside as target is raised, but earnings miss may limit gains

Evidence & confidence

Target increase suggests confidence, yet Q2 miss could temper investor enthusiasm.

Market effects

Sector

Biotech sector may see slight uplift from analyst optimism on Syndax.

Regional

U.S. biotech stocks could experience modest buying pressure.

Global

Limited to investors tracking small-cap biotech earnings.

Counterpoint

What could challenge this read

Earnings miss may signal deeper challenges, making the target raise premature.

Key entities

  • Company
    Syndax Pharmaceuticals

    Biotech firm developing axatilimab for lung fibrosis.

  • Research Firm
    H.C. Wainwright

    Equity research house issuing the Buy rating.

Read at source← All news

Related articles

OCT 12
$SNDXHighAI 8/10

Syndax Pharmaceuticals stock tumbles on failed IPF trial

Syndax Pharmaceuticals (SNDX) shares dropped 15% after its axatilimab drug failed to meet the primary endpoint in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF). The trial did not show a significant decline in forced vital capacity (FVC). The company will not pursue further IPF development but continues trials for chronic graft-versus-host disease (cGVHD) and other indications.

investing.com2 min
OCT 12
$SNDXMedAI 8/10

A lung-fibrosis drug missed its trial goal. Syndax does not plan to develop it further.

Syndax Pharmaceuticals (SNDX) announced that its Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of reducing lung function decline. The drug was well tolerated but will not be developed further for IPF. Ongoing trials in chronic graft-versus-host disease (cGVHD) continue, with results expected later this year and in early 2028. The company remains focused on advancing axatilimab and revumenib in other indications.

stocktitan.net2 min
AUG 12
$SNDXMedAI 8/10

Syndax (SNDX) Q2 2026 Earnings Call Transcript

Syndax (SNDX) discussed its Q2 2026 earnings call, focusing on menin inhibitor Revuforj and axatilimab-related pipeline. Revuforj net revenue was $55 million, up 12% QoQ, with about 1,500 prescriptions, up 15% QoQ. Niktimvo Q2 net revenue rose to $60 million, up 67% YoY. The company reiterated expectations for Revuforj peak US net revenue above $2 billion.

yahoo.com7 min